Agile Therapeutics has combined with Insud Pharma's US Subsidiary, Exeltis USA, Inc., expanding an already significant women's health/contraceptive portfolio
Dublin, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The "Agile Leadership for Pharma and Biopharma Professionals in a hybrid world Training Course" conference has been added to ResearchAndMarkets.com's offering.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Agile Therapeutics, Inc. (OTC: AGRX) to Insud Pharma, S.L. Under the terms of the proposed transaction, shareholders of Agile will receive $1.52 in cash for each share of Agile that they own. KSF is seeking to det...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Agile Therapeutics, Inc. (OTCQB: AGRX) to Insud Pharma, S.L. for $1.52 per share in cash is fair to Agile shareholders. Halper Sadeh encourages Agile shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-006...
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update.
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a....
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.